140 related articles for article (PubMed ID: 11601756)
1. Optimization of retroviral vector generation for clinical application.
Schilz AJ; Kühlcke K; Fauser AA; Eckert HG
J Gene Med; 2001; 3(5):427-36. PubMed ID: 11601756
[TBL] [Abstract][Full Text] [Related]
2. Clinical grade vector production: analysis of yield, stability, and storage of gmp-produced retroviral vectors for gene therapy.
Wikström K; Blomberg P; Islam KB
Biotechnol Prog; 2004; 20(4):1198-203. PubMed ID: 15296448
[TBL] [Abstract][Full Text] [Related]
3. Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in cell factories.
Przybylowski M; Hakakha A; Stefanski J; Hodges J; Sadelain M; Rivière I
Gene Ther; 2006 Jan; 13(1):95-100. PubMed ID: 16177816
[TBL] [Abstract][Full Text] [Related]
4. A bicistronic retroviral vector to introduce drug resistance genes into human umbilical cord blood CD34+ cells to improve combination chemotherapy tolerance.
Wang J; Chen Z; Xia X; Lu D; Xue J; Ruan C
Chin Med J (Engl); 2001 Jan; 114(1):25-9. PubMed ID: 11779430
[TBL] [Abstract][Full Text] [Related]
5. Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production.
Forestell SP; Böhnlein E; Rigg RJ
Gene Ther; 1995 Dec; 2(10):723-30. PubMed ID: 8750011
[TBL] [Abstract][Full Text] [Related]
6. State-of-the-art of the production of retroviral vectors.
Merten OW
J Gene Med; 2004 Feb; 6 Suppl 1():S105-24. PubMed ID: 14978755
[TBL] [Abstract][Full Text] [Related]
7. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
[TBL] [Abstract][Full Text] [Related]
8. Reliable generation of stable high titer producer cell lines for gene therapy.
Rattmann I; Kleff V; Feldmann A; Ludwig C; Sorg UR; Opalka B; Moritz T; Flasshove M
Intervirology; 2007; 50(3):197-203. PubMed ID: 17283445
[TBL] [Abstract][Full Text] [Related]
9. Retroviral vector production under serum deprivation: The role of lipids.
Rodrigues AF; Carmo M; Alves PM; Coroadinha AS
Biotechnol Bioeng; 2009 Dec; 104(6):1171-81. PubMed ID: 19655394
[TBL] [Abstract][Full Text] [Related]
10. Optimization of a retroviral vector for transduction of human CD34 positive cells.
Szyda A; Paprocka M; Krawczenko A; Lenart K; Heimrath J; Grabarczyk P; Mackiewicz A; Duś D
Acta Biochim Pol; 2006; 53(4):815-23. PubMed ID: 17160143
[TBL] [Abstract][Full Text] [Related]
11. A novel human suspension culture packaging cell line for production of high-titre retroviral vectors.
Chan LM; Coutelle C; Themis M
Gene Ther; 2001 May; 8(9):697-703. PubMed ID: 11406764
[TBL] [Abstract][Full Text] [Related]
12. Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome.
Hong Y; Yu SS; Kim JM; Lee K; Na YS; Whitley CB; Sugimoto Y; Kim S
J Gene Med; 2003 Jan; 5(1):18-29. PubMed ID: 12516048
[TBL] [Abstract][Full Text] [Related]
13. Closed hollow-fiber bioreactor: a new approach to retroviral vector production.
Pan D; Whitley CB
J Gene Med; 1999; 1(6):433-40. PubMed ID: 10753069
[TBL] [Abstract][Full Text] [Related]
14. Generation of retroviral packaging and producer cell lines for large-scale vector production and clinical application: improved safety and high titer.
Sheridan PL; Bodner M; Lynn A; Phuong TK; DePolo NJ; de la Vega DJ; O'Dea J; Nguyen K; McCormack JE; Driver DA; Townsend K; Ibañez CE; Sajjadi NC; Greengard JS; Moore MD; Respess J; Chang SM; Dubensky TW; Jolly DJ; Sauter SL
Mol Ther; 2000 Sep; 2(3):262-75. PubMed ID: 10985957
[TBL] [Abstract][Full Text] [Related]
15. 10-year stability of clinical-grade serum-free γ-retroviral vector-containing medium.
Herbst F; Ball CR; Zavidij O; Fessler S; Schmidt M; Veelken H; von Kalle C; Glimm H
Gene Ther; 2011 Feb; 18(2):210-2. PubMed ID: 21068779
[TBL] [Abstract][Full Text] [Related]
16. Comparison of different bioreactor systems for the production of high titer retroviral vectors.
Merten OW; Cruz PE; Rochette C; Geny-Fiamma C; Bouquet C; Gonçalves D; Danos O; Carrondo MJ
Biotechnol Prog; 2001; 17(2):326-35. PubMed ID: 11312711
[TBL] [Abstract][Full Text] [Related]
17. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91.
Sugimoto Y; Tsukahara S; Sato S; Suzuki M; Nunoi H; Malech HL; Gottesman MM; Tsuruo T
J Gene Med; 2003 May; 5(5):366-76. PubMed ID: 12731085
[TBL] [Abstract][Full Text] [Related]
18. Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium.
Glimm H; Flügge K; Möbest D; Hofmann VM; Postmus J; Henschler R; Lange W; Finke J; Kiem HP; Schulz G; Rosenthal F; Mertelsmann R; von Kalle C
Hum Gene Ther; 1998 Apr; 9(6):771-8. PubMed ID: 9581900
[TBL] [Abstract][Full Text] [Related]
19. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.
Ghani K; Cottin S; Kamen A; Caruso M
Gene Ther; 2007 Dec; 14(24):1705-11. PubMed ID: 17928873
[TBL] [Abstract][Full Text] [Related]
20. Effects of culture parameters on the production of retroviral vectors by a human packaging cell line.
McTaggart S; Al-Rubeai M
Biotechnol Prog; 2000; 16(5):859-65. PubMed ID: 11027182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
